Induction outcome by patients characteristics
| Characteristic . | CR (n = 51) . | NR (n = 31) . | Death (n = 38) . | Total (n = 120) . | P5-150 . |
|---|---|---|---|---|---|
| Age, y | |||||
| <70 | 26 (48%) | 10 (19%) | 18 (33%) | 54 | .28 |
| ≥70 | 25 (38%) | 20 (30%) | 21 (32%) | 66 | |
| Sex | |||||
| Male | 26 (39%) | 14 (21%) | 27 (40%) | 67 | .11 |
| Female | 25 (47%) | 16 (30%) | 12 (23%) | 53 | |
| Race | |||||
| White | 45 (42%) | 28 (26%) | 34 (32%) | 107 | .81 |
| Other | 6 (46%) | 2 (15%) | 5 (38%) | 13 | |
| Creatinine, mg/dL (μM/L) | |||||
| <1.0 (88.5) | 26 (45%) | 16 (28%) | 16 (28%) | 58 | .54 |
| ≥1.0 (88.5) | 25 (40%) | 14 (23%) | 23 (37%) | 62 | |
| Bilirubin, mg/dL (μM/L) | |||||
| <0.6 (10.27) | 22 (45%) | 15 (31%) | 12 (24%) | 49 | .21 |
| ≥0.6 (10.27) | 28 (41%) | 14 (20%) | 27 (39%) | 69 | |
| Left ventricular ejection fraction | |||||
| <60% | 23 (43%) | 12 (22%) | 19 (35%) | 54 | .76 |
| ≥60% | 21 (46%) | 12 (26%) | 13 (28%) | 46 | |
| Disease | |||||
| De novo | 35 (43%) | 21 (26%) | 26 (32%) | 82 | .44 |
| Prior MDS | 10 (36%) | 6 (21%) | 12 (43%) | 28 | |
| Prior chemotherapy/radiation therapy | 6 (60%) | 3 (30%) | 1 (10%) | 10 | |
| FAB | |||||
| M1 | 12 (50%) | 5 (21%) | 7 (29%) | 24 | .09 |
| M2 | 22 (49%) | 15 (33%) | 8 (18%) | 45 | |
| M4 | 7 (35%) | 5 (25%) | 8 (40%) | 20 | |
| Others | 10 (32%) | 5 (16%) | 16 (52%) | 31 | |
| Cytogenetic risk | |||||
| Low | 3 (50%) | 1 (17%) | 2 (33%) | 6 | .04 |
| Intermediate | 32 (54%) | 11 (19%) | 16 (27%) | 59 | |
| High | 2 (13%) | 6 (40%) | 7 (47%) | 15 | |
| MRK16 staining5-151 | |||||
| <0.10 | 13 (57%) | 6 (26%) | 4 (17%) | 23 | .66 |
| ≥0.10 | 22 (51%) | 9 (21%) | 12 (28%) | 43 | |
| DiOC2(3) efflux5-151 | |||||
| <0.20 | 16 (70%) | 3 (13%) | 4 (17%) | 23 | .17 |
| ≥0.20 | 19 (44%) | 12 (28%) | 12 (28%) | 43 |
| Characteristic . | CR (n = 51) . | NR (n = 31) . | Death (n = 38) . | Total (n = 120) . | P5-150 . |
|---|---|---|---|---|---|
| Age, y | |||||
| <70 | 26 (48%) | 10 (19%) | 18 (33%) | 54 | .28 |
| ≥70 | 25 (38%) | 20 (30%) | 21 (32%) | 66 | |
| Sex | |||||
| Male | 26 (39%) | 14 (21%) | 27 (40%) | 67 | .11 |
| Female | 25 (47%) | 16 (30%) | 12 (23%) | 53 | |
| Race | |||||
| White | 45 (42%) | 28 (26%) | 34 (32%) | 107 | .81 |
| Other | 6 (46%) | 2 (15%) | 5 (38%) | 13 | |
| Creatinine, mg/dL (μM/L) | |||||
| <1.0 (88.5) | 26 (45%) | 16 (28%) | 16 (28%) | 58 | .54 |
| ≥1.0 (88.5) | 25 (40%) | 14 (23%) | 23 (37%) | 62 | |
| Bilirubin, mg/dL (μM/L) | |||||
| <0.6 (10.27) | 22 (45%) | 15 (31%) | 12 (24%) | 49 | .21 |
| ≥0.6 (10.27) | 28 (41%) | 14 (20%) | 27 (39%) | 69 | |
| Left ventricular ejection fraction | |||||
| <60% | 23 (43%) | 12 (22%) | 19 (35%) | 54 | .76 |
| ≥60% | 21 (46%) | 12 (26%) | 13 (28%) | 46 | |
| Disease | |||||
| De novo | 35 (43%) | 21 (26%) | 26 (32%) | 82 | .44 |
| Prior MDS | 10 (36%) | 6 (21%) | 12 (43%) | 28 | |
| Prior chemotherapy/radiation therapy | 6 (60%) | 3 (30%) | 1 (10%) | 10 | |
| FAB | |||||
| M1 | 12 (50%) | 5 (21%) | 7 (29%) | 24 | .09 |
| M2 | 22 (49%) | 15 (33%) | 8 (18%) | 45 | |
| M4 | 7 (35%) | 5 (25%) | 8 (40%) | 20 | |
| Others | 10 (32%) | 5 (16%) | 16 (52%) | 31 | |
| Cytogenetic risk | |||||
| Low | 3 (50%) | 1 (17%) | 2 (33%) | 6 | .04 |
| Intermediate | 32 (54%) | 11 (19%) | 16 (27%) | 59 | |
| High | 2 (13%) | 6 (40%) | 7 (47%) | 15 | |
| MRK16 staining5-151 | |||||
| <0.10 | 13 (57%) | 6 (26%) | 4 (17%) | 23 | .66 |
| ≥0.10 | 22 (51%) | 9 (21%) | 12 (28%) | 43 | |
| DiOC2(3) efflux5-151 | |||||
| <0.20 | 16 (70%) | 3 (13%) | 4 (17%) | 23 | .17 |
| ≥0.20 | 19 (44%) | 12 (28%) | 12 (28%) | 43 |